Skip to content

The Clinical Effect of i-FACTOR® Versus Allograft in Non-instrumented Posterolateral Fusion The IVANOS-study

RCT Comparing i-FACTOR and Allograft in Spinal Fusion Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02895555
Acronym
IVANOS
Enrollment
102
Registered
2016-09-09
Start date
2012-03-31
Completion date
2020-09-30
Last updated
2024-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Back Pain, Spinal Stenosis

Keywords

Oswestry disability index (ODI)

Brief summary

The average life expectancy in Denmark is increasing resulting in an increasing part of the population having age-related disease, ex lumbar spinal stenosis (LSS). LSS causes constriction of the nerves in the lumbar spine resulting in pain in the legs and lower back, especially when standing and walking, known as neurogenic claudicatio(Goh KJ FAU - Khalifa et al.). LSS occurs in a combination of degenerative changes in the lower back, including hypertrophy of the ligamentum flavum, arthrosis of the facet joints and bulging of the disc. Current treatment of LSS is varied ranging from non-operative conservative treatment to operation. Operative intervention shows very good results according to physical ability and pain(Christensen FB et al.;Hee HT and Wong;McGregor AH FAU - Hughes and Hughes;Xu et al.), but the most optimal treatment is still debated. Nevertheless, a decompression and, if needed, a spinal fusion is recommended. The investigators want to se whether i-FACTOR improves clinical outcomes compared to using allograft in spinal fusion in the elderly, and thereby find an improved methods operating this difficult patient population. The hypothesis is, that there is no difference in clinical outcomes whether you use i-FACTOR or allograft i non-instrumented spinal fusion surgery in patients with spinal stenosis due to degenerative listhesis.

Detailed description

Se above

Interventions

PROCEDUREi-FACTOR

Between 5-10 CC i-FACTOR putty mixed with local harvested autograft pr level spondylodesis compared to 30 grams of allograft pr level mixed with local harvested allograft.

PROCEDUREAllograft

Approx 50 g of allograft bone in the fused site

Sponsors

Ortotech
CollaboratorUNKNOWN
CeraPedics, Inc
CollaboratorINDUSTRY
Spine Centre of Southern Denmark
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
60 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

1. Spinal stenosis, listhesis grade 1-2 (\>3 mm), facet joint arthrosis and flavum hypertrophia verified by a mr-scan and x-ray including maximally 2 levels ranging from L1-S1. 2. A score of 6 and more on Konno´s History of Examination Characteristic. 3. Signed informed content.

Exclusion criteria

1. Any disease demanding obligate thromboprophylaxis treatment, including mechanical valve, (DVT with cancer/thrombophilia, AMI, apoplexia cerebri, TCI, valve-operation)\< 3 months, coronar metal stent \< 6 weeks and coronar drug eluted/coated stent \< 12 months. 2. Atrial fibrillation and one of the following: Mitral stenosis, valve prothesis and apoplexia cerebri/TCI. 3. Atrial fibrillation and two of the following: Heart insufficient, HT, DM, age \> 75 years, EF \< 35 %. 4. Known cancer in the axial skeleton. 5. Ongoing chemotherapy. 6. Fracture i the lower back within a year prior to inclusion. 7. Reduced distance of walking due to non-spinal related causes. 8. Candidate for more than two-level intervention. 9. Dementia assessed by the MMSE 10. ASA 3+4 11. Age below 60 years. 12. Missed 3 months of conservative treatment without success 13. The use of steroids and bisphosphonates. 14. Prior radiotherapy to the lower back. 15. Haematologic disease. -

Design outcomes

Primary

MeasureTime frameDescription
Oswestry disability indexAt 60 monthsquestionnaire

Secondary

MeasureTime frameDescription
Dallas pain questionnaireAt 24 monthsquestionnaire
Walking distanceAt 24 monthsmeasuring distance
EQ5DAt 60 monthsquestionnaire
SF-36At 60 monthsquestionnaire
Fusion status yes/noAt 60 monthsObtained by CT-scan

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026